详情页

当前位置：首页 > 详情页

A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer

7| 认领 | 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究单位： [1]Qilu Pharmaceutical Co., Ltd. [2]Oncology Department, Anhui Cancer Hospital Hefei, Anhui, China, 233004 [3]Respiratory Department, Anhui Cancer Hospital Hefei, Anhui, China, 233004 [4]Cancer Institute and Hospital, Chinese Academy of Medical Sciences Beijing, Beijing, China, 100021 [5]Chinese PLA General Hospital Beijing, Beijing, China, 100039 [6]Thoracic Oncology I Department, Beijing Cancer Hospital Beijing, Beijing, China, 100142 [7]Thoracic Oncology II Department, Beijing Cancer Hospital Beijing, Beijing, China, 100142 [8]Peking Union Medical College Hospital Beijing, Beijing, China, 100730 [9]Beijing Chest Hospital Beijing, Beijing, China, 101149 [10]General Department, Beijing Chest Hospital, Capital Medical University Beijing, Beijing, China, 101149 [11]Army Medical Center of PLA Chongqing, Chongqing, China, 400042 [12]Fujian Cancer Hospital Fuzhou, Fujian, China, 350014 [13]Gansu Cancer Hospital Lanzhou, Gansu, China, 620100 [14]Cancer Center of Guangzhou Medical University Guangzhou, Guangdong, China, 510095 [15]Liuzhou People's Hospital Liuzhou, Guangxi, China, 545006 [16]The Fourth Hospital of Hebei Medical University Shijiangzhuang, Hebei, China, 050019 [17]Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China, 150000 [18]Henan Cancer Hospital Zhengzhou, Henan, China, 450008 [19]Hubei Cancer Hospital Wuhan, Hubei, China, 430070 [20]Hunan Tumor Hospital Changsha, Hunan, China, 410006 [21]The Affiliated Hospital of Inner Mongolia Medical University Hohhot, Inner Mongolia, China, 010000 [22]Nanjing Chest Hospital Nanjing, Jiangsu, China, 210029 [23]The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China, 215006 [24]The Affiliated Hospital of Jiangnan University Wuxi, Jiangsu, China, 214062 [25]Xuzhou Central Hospital Xuzhou, Jiangsu, China, 221009 [26]The First Hospital of Jilin University Changchun, Jilin, China, 130021 [27]Jilin Cancer Hospital Changchun, Jilin, China, 132000 [28]The First Hospital of China Medical University Shenyang, Liaoning, China, 110001 [29]Qilu Hospital of Shandong University Jinan, Shandong, China, 250012 [30]Jinan Central Hospital Jinan, Shandong, China, 250013 [31]Shandong Cancer Hospital Jinan, Shandong, China, 250117 [32]The Affiliated Hospital of Qingdao University Qingdao, Shandong, China, 266555 [33]Yantai Yuhuangding Hospital Yantai, Shandong, China, 264000 [34]Shanxi Cancer Hospital Taiyuan, Shanxi, China, 030013 [35]Tangdu Hospital Xi'an, Shanxi, China, 710038 [36]Affiliated Hospital of North Sichuan Medical College Nanchong, Sichuan, China, 637000 [37]Tianjin Cancer Hospital Tianjin, Tianjin, China, 300060 [38]Cancer Hospital Affiliated to Xinjiang Medical University Ürümqi, Xinjiang, China, 830011 [39]Yunnan Cancer Hospital Kunming, Yunnan, China, 650100 [40]Hangzhou first people's Hospital Hangzhou, Zhejiang, China, 310006 [41]Zhejiang Cancer Hospital Hangzhou, Zhejiang, China, 310022 [42]The First Affiliated Hospital of Anhui Medical University Hefei, Anhui, China, 230022

研究目的：

The purpose of the study is to evaluate safety and efficacy of WX-0593 oral tablets in ALK -positive, or ROS1-positive non-small cell lung cancer (NSCLC)